The polyMAC has been applied to tissue phosphoproteomics in transgenic mouse model of HER2 positive breast cancer and identified potential therapeutic targets.36 Phosphoproteomics has also been applied to directly identify kinase inhibitor targets in cancer cell lines and mouse xenografts.43 Though these studies show the promise of phosphoproteomics to provide new targets for designing anticancer therapies, most current approaches are not accessible to individualized human tissue analysis yet. This evidence concerns the gene ERBB2 and breast carcinoma.